Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06770010 · ClinicalTrials.gov registry record · NA

Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease

A NA study of Sickle Cell Disease, sponsored by Children's National Research Institute.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT06770010 is a NA study of Sickle Cell Disease that is actively recruiting participants, run by Children's National Research Institute. The registered enrollment target is 50 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06770010, a NA study of Sickle Cell Disease, is actively recruiting participants, sponsored by Children's National Research Institute.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This is a single site nonrandomized pilot clinical trial of the feasibility, acceptability, and efficacy of a combination treatment involving digital Cogmed working memory skills training, social support components, and memory strategy training to improve adherence to Cogmed in youth with sickle cell disease ages 7-16 years.

Conditions Studied

Interventions

  • BEHAVIORAL Cogmed+

Study Locations (1)

District of Columbia

  • Children's National Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-03-05
Est. Completion 2026-04-01
Phase NA

What the Registry Record Tells You About NCT06770010

The ClinicalTrials.gov registry entry for NCT06770010 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (83% lower). The listed sponsor is Children's National Research Institute, which has 92 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Cogmed+ is the first listed.

NCT06770010 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT06770010 about?

NCT06770010 is a clinical study titled "Advancing Feasibility and Acceptability of Digital Cognitive Rehabilitation in Sickle Cell Disease". This is a single site nonrandomized pilot clinical trial of the feasibility, acceptability, and efficacy of a combination treatment involving digital Cogmed working memory skills training, social support components, and memory strategy training to improve adherence to Cogmed in youth with sickle cel...

What is the current status of trial NCT06770010?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-03-05. Estimated completion is 2026-04-01.

What conditions does trial NCT06770010 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT06770010?

The interventions under investigation include: Cogmed+ (BEHAVIORAL).

Who is sponsoring clinical trial NCT06770010?

This trial is sponsored by Children's National Research Institute, which has 92 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06770010 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.